ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · Ann Rheum Dis · 2026-08-07

In 670 biologic-naïve adults with active psoriatic arthritis, oral deucravacitinib 6 mg once daily beat placebo for ACR20 at week 16 (54.2% vs 34.1%, P<.001), with responses increased at week 52 and low serious adverse events (1.8% vs 2.4%).

RCTn = 670
van der Heijde et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial
Dermatology · Br J Dermatol · 2026-07-17

Phase II trial in 94 patients with alopecia areata: deucravacitinib 6 mg once or twice daily vs placebo showed no meaningful difference in SALT score change at week 24 (adjusted differences 1.5 and 8.2) or secondary endpoints; efficacy endpoints were not met.

RCTn = 94
King et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial
Rheumatology · Ann Rheum Dis · 2026-05-12

Post hoc analysis of a phase 2 SLE trial (363 patients, 56 healthy volunteers): whole blood RNA-seq showed deucravacitinib modulated up to 2529 genes, including interferon-regulated genes, reduced plasma cell gene sets and normalised myeloid gene sets.

Secondary analysisn = 363
Vital et al. Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.